Bevacizumab biosimilar (JHL Biotech)

贝伐珠单抗生物类似药（喜康生技）

Report date: 2022/03/15 11:37:57

Base Information

Drug NameBevacizumab biosimilar (JHL Biotech)
Drug Alias Name贝伐人源化单抗生物仿制药（喜康生技）贝伐赛珠单抗生物仿制药（喜康生技）贝伐珠单抗生物仿制药（喜康生技）贝伐单抗生物仿制药（喜康生技）JHL-1149
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEden Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEden Biologics IncXikang (Wuhan) Biomedicine Co Ltd
Inactive CompaniesJhl Biotech Usa Inc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A